Iovance Biotherapeutics Stock Rises Amid Positive Clinical Trial Data
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 26 2022
0mins
Should l Buy IOVA?
Source: globenewswire
Iovance Biotherapeutics Inc. stock rose by 6.63% and reached a 52-week high, reflecting strong investor interest amid a challenging market backdrop.
The increase in stock price is attributed to the positive clinical trial data showing a 50% objective response rate for its TIL cell therapy in advanced soft-tissue sarcomas, which enhances investor confidence in the company's product pipeline. Additionally, the stock is trading significantly above its 20-day and 100-day SMA, indicating robust momentum despite the broader market's decline, with the Nasdaq-100 down 0.18% and the S&P 500 down 0.51%.
This upward movement suggests that investors are optimistic about Iovance's future prospects, particularly with the promising results from its clinical trials and the potential for market expansion.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IOVA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IOVA
Wall Street analysts forecast IOVA stock price to rise
8 Analyst Rating
6 Buy
1 Hold
1 Sell
Moderate Buy
Current: 3.510
Low
1.50
Averages
9.50
High
17.00
Current: 3.510
Low
1.50
Averages
9.50
High
17.00
About IOVA
Iovance Biotherapeutics, Inc. is a commercial biotechnology company. The Company is focused on developing and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer. Its products include Amtagvi and Proleukin. Amtagvi is indicated for the treatment of adult patients with melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor, with or without a MEK inhibitor. It is marketing Proleukin (aldesleukin), an interleukin-2 (IL-2) product used in the Amtagvi treatment regimen and in other applications. Amtagvi and Proleukin are part of a treatment regimen that includes lymphodepletion. Its development pipeline includes multicenter trials of TIL cell therapies in additional treatment settings and indications for solid tumor cancers. Its TIL therapy includes melanoma, non-small cell lung cancer and gynecologic cancer.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Avaí Bio Initiates Master Cell Bank Manufacturing
- Market Potential: The regenerative medicine market is projected to reach $578 billion by 2033, with cell therapy alone surpassing $8.2 billion this year, indicating significant growth potential that attracts investor interest.
- Manufacturing Challenge Solution: Avaí Bio has initiated the manufacturing of a Master Cell Bank for genetically modified cells overexpressing α-Klotho in collaboration with Austrianova, aiming to address the production bottlenecks in cell therapy and lay the groundwork for future commercialization.
- Innovative Delivery Mechanism: Austrianova's Cell-in-a-Box® technology protects therapeutic cells within a biocompatible shell, allowing continuous secretion of α-Klotho, which eliminates the manufacturing and logistical burdens of patient-specific autologous therapies, transforming it into a scalable product.
- Dual-Program Strategy: Avaí Bio's dual-program approach targets both the Klothonova α-Klotho anti-aging platform and the Insulinova diabetes program, expected to tap into multi-billion dollar markets, showcasing the company's strategic positioning in the regenerative medicine sector.
See More
Avaí Bio Initiates Master Cell Bank Manufacturing
- Market Potential: The regenerative medicine market is projected to reach $578 billion by 2033, with cell therapy alone surpassing $8.2 billion this year, indicating strong growth potential that attracts investor interest.
- Manufacturing Challenges: The primary bottleneck for cell therapy companies is how to manufacture living therapeutics reliably and affordably at scale, and those who solve this issue will dominate the market.
- Innovative Technology: Avaí Bio has initiated the manufacturing of a Master Cell Bank of genetically modified cells overexpressing the α-Klotho protein in collaboration with Austrianova, utilizing Cell-in-a-Box® technology to ensure continuous secretion of the protein without immune rejection.
- Broad Market Demand: α-Klotho is linked to various diseases such as Alzheimer's, cardiovascular disease, and kidney disease, presenting significant market opportunities, and Avaí Bio's dual-program approach aims to effectively address treatment needs in these areas.
See More
Avaí Bio Initiates Key Cell Bank Project for Therapy Development
- Market Outlook: The regenerative medicine market is projected to reach $578 billion by 2026, with cell therapy alone surpassing $8.2 billion this year, indicating strong growth potential that attracts investor interest.
- Infrastructure Development: Avaí Bio has initiated the creation of a Master Cell Bank (MCB) for the α-Klotho protein in collaboration with Austrianova, ensuring a standardized foundation for future cell therapies, enhancing the feasibility and consistency of product development.
- Scientific Research Support: The α-Klotho protein is extensively studied and linked to reduced risks of Alzheimer's, cardiovascular diseases, and certain cancers, with a significant market potential, as the Alzheimer's market is expected to reach $32.8 billion by 2033.
- Dual-Program Strategy: Avaí Bio's Insulinova platform also utilizes Cell-in-a-Box® technology to target diabetes, showcasing the company's diversified approach in the cell therapy field, thereby enhancing its competitive position in the market.
See More
Avaí Bio Initiates Key Cell Bank Project for Therapy Development
- Market Potential: The regenerative medicine market is projected to reach $578 billion by 2033, with cell therapy alone surpassing $8.2 billion in 2026, indicating a rapid growth trajectory that is attracting significant investment and research resources.
- Infrastructure Importance: Avaí Bio has initiated a Master Cell Bank (MCB) project in collaboration with Austrianova to create a standardized cellular starting material by cloning a single genetically engineered cell into tens of millions of identical copies, ensuring consistency and scalability for future therapy development.
- Clinical Application Outlook: The α-Klotho protein is linked to various age-related diseases, with the Alzheimer's market expected to reach $32.8 billion by 2033, positioning Avaí Bio's research to potentially achieve groundbreaking advancements in these critical health areas.
- Technological Innovation and Market Competitiveness: Avaí Bio's Insulinova platform also leverages Cell-in-a-Box® technology to address diabetes by protecting therapeutic cells, showcasing the company's innovative capabilities and competitive edge in the cell therapy landscape.
See More
How Two Small Biotech Companies Could Pave the Way for Innovative Cancer Therapies
Cancer as a Medical Challenge: Cancer remains a significant challenge for biotechnology firms, with the oncology market projected to surge to $366 billion in the next 80 years, prompting companies to develop targeted treatments for specific cancer types.
Promising Treatments and Market Growth: Several promising cancer treatments have shown incredible potential, leading to significant sales opportunities for biotech firms, particularly those focusing on oncology medicines.
Iovance's Market Performance: Iovance Biotherapeutics has experienced substantial share price growth, driven by its leading cancer drug, which has the potential to generate over $1 billion in U.S. sales, despite facing production challenges.
Immunity Bio's Growth and Challenges: Immunity Bio has seen impressive sales growth for its bladder cancer drug, Anktiva, following regulatory approvals, but it still faces risks and challenges in manufacturing and market competition.
See More
Iovance Biotherapeutics Stock Rises Amid High Short Interest
- Short Interest Pressure: Iovance Biotherapeutics has a high short interest of 39.6%, which, against a market cap of $1.66 billion, indicates market caution regarding its future performance and could lead to increased stock volatility.
- Positive Clinical Trial Data: The company reported a 50% objective response rate in its TIL cell therapy clinical trial for advanced soft-tissue sarcomas, suggesting potential for new market opportunities and enhancing investor confidence in its product pipeline.
- Strong Stock Performance: The stock is trading 59.6% above its 20-day SMA and 98.5% above its 100-day SMA, reflecting robust upward momentum over the past year, although the RSI at 83.41 indicates it may be overbought and due for a pullback.
- Optimistic Analyst Ratings: Iovance's stock carries a Buy rating with an average price target of $11.23, and recent upward adjustments in analysts' targets reflect growing confidence in its future growth, further supporting the upward trend in its stock price.
See More
Avaí Bio Initiates Master Cell Bank Manufacturing
- Market Potential: The regenerative medicine market is projected to reach $578 billion by 2033, with cell therapy alone surpassing $8.2 billion this year, indicating significant growth potential that attracts investor interest.
- Manufacturing Challenge Solution: Avaí Bio has initiated the manufacturing of a Master Cell Bank for genetically modified cells overexpressing α-Klotho in collaboration with Austrianova, aiming to address the production bottlenecks in cell therapy and lay the groundwork for future commercialization.
- Innovative Delivery Mechanism: Austrianova's Cell-in-a-Box® technology protects therapeutic cells within a biocompatible shell, allowing continuous secretion of α-Klotho, which eliminates the manufacturing and logistical burdens of patient-specific autologous therapies, transforming it into a scalable product.
- Dual-Program Strategy: Avaí Bio's dual-program approach targets both the Klothonova α-Klotho anti-aging platform and the Insulinova diabetes program, expected to tap into multi-billion dollar markets, showcasing the company's strategic positioning in the regenerative medicine sector.
See More
Avaí Bio Initiates Master Cell Bank Manufacturing
- Market Potential: The regenerative medicine market is projected to reach $578 billion by 2033, with cell therapy alone surpassing $8.2 billion this year, indicating strong growth potential that attracts investor interest.
- Manufacturing Challenges: The primary bottleneck for cell therapy companies is how to manufacture living therapeutics reliably and affordably at scale, and those who solve this issue will dominate the market.
- Innovative Technology: Avaí Bio has initiated the manufacturing of a Master Cell Bank of genetically modified cells overexpressing the α-Klotho protein in collaboration with Austrianova, utilizing Cell-in-a-Box® technology to ensure continuous secretion of the protein without immune rejection.
- Broad Market Demand: α-Klotho is linked to various diseases such as Alzheimer's, cardiovascular disease, and kidney disease, presenting significant market opportunities, and Avaí Bio's dual-program approach aims to effectively address treatment needs in these areas.
See More
Avaí Bio Initiates Key Cell Bank Project for Therapy Development
- Market Outlook: The regenerative medicine market is projected to reach $578 billion by 2026, with cell therapy alone surpassing $8.2 billion this year, indicating strong growth potential that attracts investor interest.
- Infrastructure Development: Avaí Bio has initiated the creation of a Master Cell Bank (MCB) for the α-Klotho protein in collaboration with Austrianova, ensuring a standardized foundation for future cell therapies, enhancing the feasibility and consistency of product development.
- Scientific Research Support: The α-Klotho protein is extensively studied and linked to reduced risks of Alzheimer's, cardiovascular diseases, and certain cancers, with a significant market potential, as the Alzheimer's market is expected to reach $32.8 billion by 2033.
- Dual-Program Strategy: Avaí Bio's Insulinova platform also utilizes Cell-in-a-Box® technology to target diabetes, showcasing the company's diversified approach in the cell therapy field, thereby enhancing its competitive position in the market.
See More
Avaí Bio Initiates Key Cell Bank Project for Therapy Development
- Market Potential: The regenerative medicine market is projected to reach $578 billion by 2033, with cell therapy alone surpassing $8.2 billion in 2026, indicating a rapid growth trajectory that is attracting significant investment and research resources.
- Infrastructure Importance: Avaí Bio has initiated a Master Cell Bank (MCB) project in collaboration with Austrianova to create a standardized cellular starting material by cloning a single genetically engineered cell into tens of millions of identical copies, ensuring consistency and scalability for future therapy development.
- Clinical Application Outlook: The α-Klotho protein is linked to various age-related diseases, with the Alzheimer's market expected to reach $32.8 billion by 2033, positioning Avaí Bio's research to potentially achieve groundbreaking advancements in these critical health areas.
- Technological Innovation and Market Competitiveness: Avaí Bio's Insulinova platform also leverages Cell-in-a-Box® technology to address diabetes by protecting therapeutic cells, showcasing the company's innovative capabilities and competitive edge in the cell therapy landscape.
See More
How Two Small Biotech Companies Could Pave the Way for Innovative Cancer Therapies
Cancer as a Medical Challenge: Cancer remains a significant challenge for biotechnology firms, with the oncology market projected to surge to $366 billion in the next 80 years, prompting companies to develop targeted treatments for specific cancer types.
Promising Treatments and Market Growth: Several promising cancer treatments have shown incredible potential, leading to significant sales opportunities for biotech firms, particularly those focusing on oncology medicines.
Iovance's Market Performance: Iovance Biotherapeutics has experienced substantial share price growth, driven by its leading cancer drug, which has the potential to generate over $1 billion in U.S. sales, despite facing production challenges.
Immunity Bio's Growth and Challenges: Immunity Bio has seen impressive sales growth for its bladder cancer drug, Anktiva, following regulatory approvals, but it still faces risks and challenges in manufacturing and market competition.
See More
Iovance Biotherapeutics Stock Rises Amid High Short Interest
- Short Interest Pressure: Iovance Biotherapeutics has a high short interest of 39.6%, which, against a market cap of $1.66 billion, indicates market caution regarding its future performance and could lead to increased stock volatility.
- Positive Clinical Trial Data: The company reported a 50% objective response rate in its TIL cell therapy clinical trial for advanced soft-tissue sarcomas, suggesting potential for new market opportunities and enhancing investor confidence in its product pipeline.
- Strong Stock Performance: The stock is trading 59.6% above its 20-day SMA and 98.5% above its 100-day SMA, reflecting robust upward momentum over the past year, although the RSI at 83.41 indicates it may be overbought and due for a pullback.
- Optimistic Analyst Ratings: Iovance's stock carries a Buy rating with an average price target of $11.23, and recent upward adjustments in analysts' targets reflect growing confidence in its future growth, further supporting the upward trend in its stock price.
See More
